ReviewThe Indian journal of medical research2013
New treatment strategies for Alzheimer's disease: is there a hope?
Review in The Indian journal of medical research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product.Clinical drug investigation · 2014Trial
- An update on stem cell and stem cell-derived extracellular vesicle-based therapy in the management of Alzheimer's disease.Heliyon · 2023Review
- Review
- Cationic biopolymer decorated Asiatic Acid andF1000Research · 2022Article
- Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2020Article
- The potential role of pomegranate and its nano-formulations on cerebral neurons in aluminum chloride induced Alzheimer rat model.Saudi journal of biological sciences · 2020Article
- Ongoing Research on the Role of Gintonin in the Management of Neurodegenerative Disorders.Cells · 2020Review
- Amyloid beta peptide-degrading microbial enzymes and its implication in drug design.3 Biotech · 2020Review
- Neuroprotective Effect of New Nanochelating-Based Nano Complex, ALZc3, Against AβPharmaceutical research · 2020Article
- β-Sitosterol treatment attenuates cognitive deficits and prevents amyloid plaque deposition in amyloid protein precursor/presenilin 1 mice.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2020Article
- Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease.Alzheimer's research & therapy · 2019Article
- Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia.The Indian journal of medical research · 2019Article
- Thrombospondin-1 secreted by human umbilical cord blood-derived mesenchymal stem cells rescues neurons from synaptic dysfunction in Alzheimer's disease model.Scientific reports · 2018Article
- In silico repurposing of antipsychotic drugs for Alzheimer's disease.BMC neuroscience · 2017Article
- Resveratrol and Amyloid-Beta: Mechanistic Insights.Nutrients · 2017Review
- The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease.Journal of cellular and molecular medicine · 2016Review
- Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.Frontiers in pharmacology · 2016Review
- Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer's Disease.Current medicinal chemistry · 2015Review
- RBC acetyl cholinesterase: A poor man's early diagnostic biomarker for familial alzheimer's and Parkinson's disease dementia.Journal of neurosciences in rural practice · 2015Article
- Pregnane X Receptor and P-glycoprotein: a connexion for Alzheimer's disease management.Molecular diversity · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disease, and corresponds to the most common cause of dementia worldwide. Although not fully understood, the pathophysiology of AD is largely represented by the neurotoxic events triggered by the beta-amyloid cascade and by cytoskeletal abnormalities subsequent to the hyperphosphorylation of microtubule-associated Tau protein in neurons. These processes lead respectively to the formation of neuritic plaques and neurofibrillary tangles, which are the pathological hallmarks of the disease. Clinical benefits of the available pharmacological treatment for AD with antidementia drugs (namely cholinesterase inhibitors and memantine) are unquestionable, although limited to a temporary, symptomatic support to cognitive and related functions. Over the past decade, substantial funding and research have been dedicated to the search and development of new pharmaceutical compounds with disease-modifying properties. The rationale of such approach is that by tackling key pathological processes in AD it may be possible to attenuate or even change its natural history. In the present review, we summarize the available evidence on the new therapeutic approaches that target amyloid and Tau pathology in AD, focusing on pharmaceutical compounds undergoing phase 2 and phase 3 randomized controlled trials.
Indexed as
Identifiers
24434253PMC3868059What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.